Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial
Top Cited Papers
- 18 December 2019
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 79 (3), 339-346
- https://doi.org/10.1136/annrheumdis-2019-216303
Abstract
Objectives To compare the efficacy to prevent flares of maintenance versus withdrawal of 5 mg/day prednisone in systemic lupus erythematosus (SLE) patients with clinically quiescent disease. Methods A monocentric, 12-month, superiority, open-label, randomised (1:1) controlled trial was conducted with 61 patients continuing 5 mg/day prednisone and 63 stopping it. Eligibility criteria were SLE patients who, during the year preceding the inclusion, had a clinically inactive disease and a stable SLE treatment including 5 mg/day prednisone. The primary endpoint was the proportion of patient experiencing a flare defined with the SELENA-SLEDAI flare index (SFI) at 52 weeks. Secondary endpoints included time to flare, flare severity according to SFI and British Isles Lupus Assessment Group (BILAG) index and increase in the Systemic Lupus International Collaborating Clinics (SLICC) damage index (SDI). Results Proportion of patients experiencing a flare was significantly lower in the maintenance group as compared with the withdrawal group (4 patients vs 17; RR 0.2 (95% CI 0.1 to 0.7), p=0.003). Maintenance of 5 mg prednisone was superior with respect to time to first flare (HR 0.2; 95% CI 0.1 to 0.6, p=0.002), occurrence of mild/moderate flares using the SFI (3 patients vs 12; RR 0.2 (95% CI 0.1 to 0.8), p=0.012) and occurrence of moderate/severe flares using the BILAG index (1 patient vs 8; RR 0.1 (95% CI 0.1 to 0.9), p=0.013). SDI increase and adverse events were similar in the two treatment groups. Subgroup analyses of the primary endpoint by predefined baseline characteristics did not show evidence of a different clinical response. Conclusion Maintenance of long term 5 mg prednisone in SLE patients with inactive disease prevents relapse. Trial registration number NCT02558517; ResultsKeywords
Funding Information
- Institut National de la Santé et de la Recherche Médicale
- Assistance Publique - Hôpitaux de Paris
This publication has 42 references indexed in Scilit:
- 2019 update of the EULAR recommendations for the management of systemic lupus erythematosusAnnals Of The Rheumatic Diseases, 2019
- Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational surveyLupus Science & Medicine®, 2017
- Independent association of glucocorticoids with damage accrual in SLELupus Science & Medicine®, 2016
- Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosusRheumatology, 2016
- Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus--the Hopkins Lupus CohortLupus Science & Medicine®, 2015
- Treat-to-target in systemic lupus erythematosus: recommendations from an international task forceAnnals Of The Rheumatic Diseases, 2014
- Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritisAnnals Of The Rheumatic Diseases, 2012
- EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairsAnnals Of The Rheumatic Diseases, 2010
- Prednisone, Lupus Activity, and Permanent Organ DamageThe Journal of Rheumatology, 2009
- Damage in systemic lupus erythematosus and its association with corticosteroidsArthritis & Rheumatism, 2000